Treatment of Primary Immunodeficiency with Human GammaglobulinPersio Roxo-Junior1* and Rosa Aparecida Ferreira2
1Assistant Professor, Department of Puericulture and Pediatrics, Ribeirao Preto Medical School, University of Sao Paulo, Responsible for the Service of Pediatric Allergy and Immunology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil
2Professor, Responsible for the Area of Childhood Allergy and Immunology, University Center Barão de Mauá, and Assistant Physician, Teaching Health Center, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil
- *Corresponding Author:
- Pérsio Roxo-Jr
Department of Puericulture and Pediatrics
School of Medicine of Ribeirão Preto
University of São Paulo, Avenida Bandeirantes
3900, code 14049-900, Ribeirão Preto
São Paulo State, Brazil
E-mail: [email protected]
Received date: March 11, 2013; Accepted date: April 26, 2013; Published date: April 29, 2013
Citation: Roxo-Jr P, Ferreira RA (2013) Treatment of Primary Immunodeficiency with Human Gammaglobulin. J Blood Lymph S3:001. doi:10.4172/2165-7831.S3-001
Copyright: © 2013 Roxo-Jr P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Primary immunodeficiencies are characterized by recurrent or prolonged infections associated with growth retardation, infections by specific microorganisms or by low virulence germs, inappropriate response to the antibiotics used, a high risk of complications and hospitalization and severe vaccine complications. The evaluation of immunological status is essential for the diagnosis of these diseases.
Immunoglobulin replacement therapy is the best option for most antibody deficiencies and for some diseases that do not belong to this group, like hyper IgM syndrome, immunodeficiency with thymoma and severe combined immunodeficiency. This therapy is a safe procedure that induces dramatic positive changes in the clinical outcome of patients who carry antibody defects.
An early diagnosis of primary immunodeficiencies is essential so that therapeutic measures may be taken quickly, such as the use of immunoglobulin when properly indicated, reducing the risks of death and complications.